Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Jul 25:2020:8853167.
doi: 10.1155/2020/8853167. eCollection 2020.

Isotretinoin-Induced Delusional Disorder, Somatic Subtype

Affiliations
Case Reports

Isotretinoin-Induced Delusional Disorder, Somatic Subtype

Katharine V Jensen et al. Case Rep Dermatol Med. .

Abstract

Isotretinoin, an active form of vitamin A, is the drug of last resort for the treatment of severe acne. Depression, suicidal ideation, and psychosis are among the most well-documented psychiatric side effects. Here, we report a case of isotretinoin-induced psychosis, which was diagnosed as delusional disorder somatic subtype, in a young male in the absence of any prodromal symptoms, previous psychiatric history, or family history of mental illness. The onset of psychosis was in the context of a dosage increase from 40 mg/day to 80 mg/day. Isotretinoin was discontinued, and the patient showed improvement on low-dose quetiapine.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

References

    1. Costa C. S., Bagatin E., Martimbianco A. L. C., et al. Oral isotretinoin for acne. Cochrane Database of Systematic Reviews. 2018;11(11) doi: 10.1002/14651858.cd009435.pub2. - DOI - PMC - PubMed
    1. Brzezinski P., Borowska K., Chiriac A., Smigielski J. Adverse effects of isotretinoin: a large, retrospective review. Dermatologic Therapy. 2017;30(4) doi: 10.1111/dth.12483.e12483 - DOI - PubMed
    1. Bagatin E. Oral isotretinoin: the most promising dermatological off-label uses. Expert Review of Dermatology. 2010;5(6):617–626. doi: 10.1586/edm.10.58. - DOI
    1. De Souza Leão Kamamoto C., Sanudo A., Hassun K. M., Bagatin E. Low-dose oral isotretinoin for moderate to severe seborrhea and seborrheic dermatitis: a randomized comparative trial. International Journal of Dermatology. 2017;56(1):80–85. doi: 10.1111/ijd.13408. - DOI - PubMed
    1. Henry D., Dormuth C., Winquist B., et al. Occurrence of pregnancy and pregnancy outcomes during isotretinoin therapy. Canadian Medical Association Journal. 2016;188(10):723–730. doi: 10.1503/cmaj.151243. - DOI - PMC - PubMed

Publication types

LinkOut - more resources